Literature DB >> 26404949

Immunological biomarkers in dermatomyositis.

Jeannette M Olazagasti1, Timothy B Niewold2, Ann M Reed3.   

Abstract

Dermatomyositis (DM) is a chronic acquired disorder that affects primarily the muscle and skin. The pathogenesis of DM, as well as methods for monitoring disease activity and predicting response to therapy, are subjects of active research. Studies looking to unveil the pathogenesis of DM have revealed key molecules that are potential biomarkers of disease activity. This article reviews briefly the recently discovered molecules that are candidate immunological biomarkers for diagnosing and monitoring disease activity in DM.

Entities:  

Keywords:  Biomarkers; Chemokines; Cytokines; Dermatomyositis; Toll-like receptors; Type I interferon

Mesh:

Substances:

Year:  2015        PMID: 26404949     DOI: 10.1007/s11926-015-0543-y

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  44 in total

Review 1.  Toll-like receptors in rheumatic diseases: are we paying a high price for our defense against bugs?

Authors:  K C M Santegoets; L van Bon; W B van den Berg; M H Wenink; T R D J Radstake
Journal:  FEBS Lett       Date:  2011-04-16       Impact factor: 4.124

2.  Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy.

Authors:  Mohammad Salajegheh; Sek Won Kong; Jack L Pinkus; Ronan J Walsh; Anne Liao; Remedios Nazareno; Anthony A Amato; Bryan Krastins; Chris Morehouse; Brandon W Higgs; Bahija Jallal; Yihong Yao; David A Sarracino; Kenneth C Parker; Steven A Greenberg
Journal:  Ann Neurol       Date:  2010-01       Impact factor: 10.422

3.  Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies.

Authors:  I Lundberg; A K Ulfgren; P Nyberg; U Andersson; L Klareskog
Journal:  Arthritis Rheum       Date:  1997-05

4.  Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis.

Authors:  G Chevrel; G Page; C Granet; N Streichenberger; A Varennes; P Miossec
Journal:  J Neuroimmunol       Date:  2003-04       Impact factor: 3.478

5.  Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines.

Authors:  A Tournadre; V Lenief; P Miossec
Journal:  Arthritis Rheum       Date:  2010-07

Review 6.  Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders.

Authors:  P H Plotz; M Dalakas; R L Leff; L A Love; F W Miller; M E Cronin
Journal:  Ann Intern Med       Date:  1989-07-15       Impact factor: 25.391

7.  Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis.

Authors:  Lin Yuan; Lutian Yao; Lin Zhao; Liping Xia; Hui Shen; Jing Lu
Journal:  Clin Exp Rheumatol       Date:  2013-03-13       Impact factor: 4.473

8.  Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis.

Authors:  Geun-Tae Kim; Mi-La Cho; Young-Eun Park; Wan Hee Yoo; Jung-Hee Kim; Hye-Jwa Oh; Dae-Sung Kim; Seung-Hoon Baek; Sun-Hee Lee; Jun-Hee Lee; Ho-Youn Kim; Sung-Il Kim
Journal:  Clin Rheumatol       Date:  2009-12-02       Impact factor: 2.980

9.  Resistin in idiopathic inflammatory myopathies.

Authors:  Mária Filková; Hana Hulejová; Klára Kuncová; Lenka Pleštilová; Lucie Andrés Cerezo; Heřman Mann; Martin Klein; Josef Zámečník; Steffen Gay; Jiří Vencovský; Ladislav Senolt
Journal:  Arthritis Res Ther       Date:  2012-05-11       Impact factor: 5.156

10.  Adipokine gene expression in peripheral blood of adult and juvenile dermatomyositis patients and their relation to clinical parameters and disease activity measures.

Authors:  Jeannette M Olazagasti; Molly Hein; Cynthia S Crowson; Consuelo Lopez de Padilla; Erik Peterson; Emily C Baechler; Ann M Reed
Journal:  J Inflamm (Lond)       Date:  2015-04-09       Impact factor: 4.981

View more
  4 in total

Review 1.  Update on outcome assessment in myositis.

Authors:  Lisa G Rider; Rohit Aggarwal; Pedro M Machado; Jean-Yves Hogrel; Ann M Reed; Lisa Christopher-Stine; Nicolino Ruperto
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

2.  Connective tissue diseases: Targeting type I interferon in systemic lupus erythematosus.

Authors:  Timothy B Niewold
Journal:  Nat Rev Rheumatol       Date:  2016-05-26       Impact factor: 20.543

3.  Relationship between Neutrophil-to-Lymphocyte Ratio and Systemic Lupus Erythematosus: A Meta-analysis.

Authors:  Liping Wang; Chunyan Wang; Xuqiang Jia; Minghui Yang; Jing Yu
Journal:  Clinics (Sao Paulo)       Date:  2020-04-17       Impact factor: 2.365

4.  Fashionably Late: A Case of Delayed Cutaneous Manifestations in Juvenile Dermatomyositis.

Authors:  Maya Antoine; Patrick T Reeves; Luis Rohena; Olcay Jones; Brian Faux
Journal:  J Clin Med Res       Date:  2018-10-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.